|
Aug 7
|
SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
|
|
Aug 7
|
Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
|
|
Jul 30
|
SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC
|
|
Jul 30
|
Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
|
|
Jul 30
|
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
|
|
Jul 22
|
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
|
|
Jun 24
|
SciSparc Announces 1-for-21 Reverse Share Split
|
|
Apr 25
|
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
|
|
Mar 10
|
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea
|
|
Mar 3
|
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
|
|
Feb 27
|
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax’s Entry into Direct Import of JAC Electric Vehicles
|
|
Feb 26
|
N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers
|
|
Feb 18
|
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology
|
|
Jan 2
|
IMCA renews SciSparc’s autism spectrum disorder therapy trial approval
|
|
Dec 31
|
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
|
|
Oct 1
|
SciSparc receives FDA approval for trial for Tourette syndrome therapy
|
|
Sep 30
|
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
|
|
Aug 29
|
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
|
|
Aug 28
|
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
|
|
Aug 26
|
SciSparc secures final approval in Israel to start Tourette’s Syndrome trial
|